University Of Tasmania
Browse
142410-Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy.pdf (2.16 MB)
Download file

Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy

Download (2.16 MB)
journal contribution
posted on 2023-05-20, 20:18 authored by Kourakis, S, Timpani, CA, de Haan, JB, Nuri GuvenNuri Guven, Fischer, D, Rybalka, E
Imbalances in redox homeostasis can result in oxidative stress, which is implicated in various pathological conditions including the fatal neuromuscular disease Duchenne Muscular Dystrophy (DMD). DMD is a complicated disease, with many druggable targets at the cellular and molecular level including calcium-mediated muscle degeneration; mitochondrial dysfunction; oxidative stress; inflammation; insufficient muscle regeneration and dysregulated protein and organelle maintenance. Previous investigative therapeutics tended to isolate and focus on just one of these targets and, consequently, therapeutic activity has been limited. Nuclear erythroid 2-related factor 2 (Nrf2) is a transcription factor that upregulates many cytoprotective gene products in response to oxidants and other toxic stressors. Unlike other strategies, targeted Nrf2 activation has the potential to simultaneously modulate separate pathological features of DMD to amplify therapeutic benefits. Here, we review the literature providing theoretical context for targeting Nrf2 as a disease modifying treatment against DMD.

History

Publication title

Redox Biology

Volume

38

Article number

101803

Number

101803

Pagination

1-14

ISSN

2213-2317

Department/School

School of Pharmacy and Pharmacology

Publisher

Elsevier BV

Place of publication

Netherlands

Rights statement

Copyright 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license

Repository Status

  • Open

Socio-economic Objectives

Treatment of human diseases and conditions